EODData

MEMBERSHIP REGISTER LOG IN

FRA, 3NK: ALPHAMAB ONCOLO.DL-000002

24 Mar 2026
LAST:

0.8800

CHANGE:
 0.01		OPEN:
0.8800		HIGH:
0.8800		ASK:
0.0000		VOLUME:
500
CHG(%):
1.15		PREV:
0.8700		LOW:
0.8800		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Mar 260.88000.88000.88000.8800500
23 Mar 260.87000.87000.87000.8700500
20 Mar 260.90500.90500.90500.9050500
19 Mar 260.93500.93500.93500.93500
18 Mar 260.99500.99500.99500.99500
17 Mar 260.98500.98500.98500.98500
16 Mar 260.96500.96500.96500.96500
13 Mar 260.94000.94000.94000.94000
12 Mar 260.92000.92000.92000.9200500
11 Mar 260.95000.95000.95000.9500500

PROFILE

Name:ALPHAMAB ONCOLO.DL-000002
About:Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of advanced malignant solid tumors, lung cancer, and breast cancer; KN019, an immunosuppressive agent in Phase II clinical trial for prophylaxis of organ rejection in adult patients receiving a kidney transplant; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops pre-clinical stage products for oncology comprising JSKN022, JSKN027, JSKN021, JSKN020, and JSKN028 for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Sector:Healthcare
Industry:Biotechnology
Address:No. 175 Fangzhou Road, Suzhou, China, 215127
Website:https://www.alphamabonc.com
ISIN:KYG0330A1013

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:40.67 
Price to Sales:1.54 
Price to Book:5.24 
Profit Margin:0.30 
Operating Margin:0.00 
Return on Assets:0.05 
Return on Equity:0.13 
Revenue:95.3M 
EBITDA:30.71M 
Shares:971.2M 
Market Cap:854.65M 

TECHNICAL INDICATORS

MA5:0.924.2%
MA10:0.936.2%
MA20:0.913.4%
MA50:0.969.5%
MA100:1.0519.5%
MA200:1.0620.9%
STO9:8.00 
STO14:14.81 
RSI14:58.11
WPR14:-85.19 
MTM14:0.02
ROC14:0.02 
ATR:0.03 
Week High:1.0013.1%
Week Low:0.871.1%
Month High:1.0013.1%
Month Low:0.8220.9%
Year High:1.6890.9%
Year Low:0.6437.7%
Volatility:28.59